A 6 Months NIS to Evaluate the Use of Rescue Medication and Quality of Life in Adult Asthmatic Subjects Treated With Symbicort® SMART®

Asthma treatment will not be assigned randomly, but will be administered at the discretion of the physicians according to standard medical practice. Each site should enrol 5 patients using the Symbicort® SMART® principle and 5 patients being prescribed a free combination GCS / LABA treatment.

Inclusion Criteria:

• Confirmed diagnosis of asthma demonstrating a reversible obstruction during the last 5 years prior to visit 1.
• Patients being prescribed either Symbicort SMART or a free combination of ICS and LABA with SABA as rescue inhaler and being on that treatment for at least 3 month.
• A history (documented in the patient's file) of at least one severe asthma exacerbation within 24 months prior to visit 1 but not within the last 30 days prior to Visit 1.

• A severe asthma exacerbation is defined as a deterioration of asthma leading to at least one of the following:

  • Oral/systemic GCS treatment due to asthma for at least 3 days
  • Unscheduled health-care visit due to asthmaHospitalization or emergency room visit because of asthma requiring treatment with oral/systemic GCS

Exclusion Criteria:

• Intake of oral, rectal, or parenteral GCS within 30 days prior to visit
• Use of ß-blocking agents
• Respiratory infection affecting the asthma, as judged by the investigator, within 30 days prior to visit 1.